thumbnail image
  • Company
  • Pipeline
  • News & Events
  • Careers
  • Contact
  • Company
  • Pipeline
  • News & Events
  • Careers
  • Contact
    • Pharmaceuticals discovered with AI

    • EFFICIENT DRUG DISCOVERY & DEVELOPMENT

      twoXAR Pharmaceuticals is a drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 18 diseases. twoXAR saves years in drug development while generating a 30x hit rate at in vivo efficacy milestones over traditional methods.

    • OUR PIPELINE
    • WEBINAR SERIES

      Part 1: SVP R&D, Mark Eller discusses the role of AI in the drug discovery ecosystem

      Part 2: VP Discovery, Aaron Daugherty shares how we collaborate with our partners

      Part 3: SVP Nonclinical R&D & Chemistry, Anjali Pandey provides insight on what's next for twoXAR

      LATEST NEWS

      This Year's JPM Conference Should Give Our Industry Confidence

      Andrew Radin

      January 21, 2021

      Looking Forward to 2021 at twoXAR

      Andrew Radin

      December 16, 2020

      twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates

      November 13, 2020

      LATEST EVENTS

      Innovation in Drug Research and Development for Chronic Diseases - Part 1

      National Academies of Science, Engineering, and Medicine (Virtual)

      February 22, 2021

      twoXAR Pharmaceuticals CEO Andrew A. Radin presents in a session on new technologies enabling discovery research.

      2021 MIT ILP WuXi Virtual Symposium

      MIT ILP (Digital)

      January 27, 2021

      twoXAR Pharmaceuticals CEO Andrew Radin presents at the MIT Startup Exchange Lightning Talk

      Biotech Showcase

      (Digital)

      January 11-15, 2021

      twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules.

      NEWS & EVENTS

    © 2021 twoXAR, Incorporated | All Rights Reserved

      Home
      Pipeline
      News
      Contact
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More